Target intelligence / Profile preview

Ribosomal protein SA pseudogene 22 (RPSAP22)

Target
RPSAP22
Molecular classification
Other (pseudogene; not a true ribosomal protein, receptor, or enzyme)
01

Overview

Ribosomal protein SA pseudogene 22 (RPSAP22) is a processed pseudogene that is part of the *RPSA* gene family, which includes the gene encoding ribosomal protein SA (also known as 37-kDa laminin receptor precursor/67-kDa laminin receptor, LRP/LR)[1][5]. While ribosomal protein SA itself serves as a ribosomal protein as well as a multifunctional receptor involved in cell adhesion, migration, and various pathologies including cancer and prion diseases, the pseudogene RPSAP22 is an inactive genomic sequence that does not encode a functional protein. Most *RPSA* pseudogenes were formed by retropositional events and typically carry mutations (frameshifts, premature stop codons, missing start codons) that prevent them from coding for active proteins[1]. Some RPSA pseudogenes may produce non-coding RNA with potential regulatory functions, though there is no specific evidence for RPSAP22 itself. RPSAP22 is not a druggable or therapeutic target, as it does not produce a functional product or interface with drugs or disease processes.

Other names
RPSA_5_248RPSAP22
02

Mechanism of action

None. Drugs do not target RPSAP22 as a pseudogene.

03

Biological functions

No canonical protein function; pseudogenes typically lack biological activity, but some pseudogenes may be involved in regulatory non-coding RNA roles[1]. No direct functional role has been attributed to RPSAP22.
04

Disease associations

There is no evidence that RPSAP22 itself has a disease role; functional RPSA and its active variants are implicated in cancer and prion diseases[1][3][5], but pseudogenes like RPSAP22 have not been reported to be directly involved.
05

Safety considerations

None specific to RPSAP22.
06

Interacting drugs

None. There are no drugs known to interact with RPSAP22, as it does not encode a functional protein.
07

Biomarkers

None reported for RPSAP22.

Beyond the preview

Go deeper on Ribosomal protein SA pseudogene 22 (RPSAP22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein SA pseudogene 22 (RPSAP22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call